scholarly journals Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses

2021 ◽  
Vol 8 ◽  
Author(s):  
Bianca Schulte ◽  
Benjamin Marx ◽  
Marek Korencak ◽  
Dorian Emmert ◽  
Souhaib Aldabbagh ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Tract ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Upper Respiratory Tract ◽  
Protective Measures ◽  
Specific Antibodies ◽  
Household Members ◽  
Upper Respiratory

We present a case of SARS-CoV-2 B.1. 525 infection in a healthcare worker despite the presence of highly neutralizing, multivariant-specific antibodies 7 weeks after full vaccination with the mRNA vaccine BNT162b2. We show that the virus replicated to high levels in the upper respiratory tract over the course of several days in the presence of strong antibody responses. The virus was readily propagatable in vitro, demonstrating the potential to transmit to others, bolstered by the fact that several household members were equally infected. This highlights the importance of protective measures even in vaccinated individuals.

scholarly journals Kinetics of BoHV-1 Dissemination in an in Vitro Culture of Bovine Upper Respiratory Tract Mucosa Explants

ILAR Journal ◽  
2012 ◽  
Vol 53 (1) ◽  
pp. E43-E54 ◽  
Author(s):  
L. Steukers ◽  
A. P. Vandekerckhove ◽  
W. Van den Broeck ◽  
S. Glorieux ◽  
H. J. Nauwynck
Keyword(s):  
Respiratory Tract ◽  
In Vitro Culture ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Kinetics Of

scholarly journals Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP

2021 ◽  
Vol 218 (7) ◽  
Author(s):  
Laura Solforosi ◽  
Harmjan Kuipers ◽  
Mandy Jongeneelen ◽  
Sietske K. Rosendahl Huber ◽  
Joan E.M. van der Lubbe ◽  
...  
Keyword(s):  
Single Dose ◽  
Protective Efficacy ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Upper Respiratory Tract ◽  
T Helper ◽  
Th Cell ◽  
Upper Respiratory ◽  
Early Indication ◽  
Dose Vaccine

Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.

scholarly journals Assessment of Postvaccine Immunity against Streptococcus pneumoniae in Patients with Asplenia, including an Analysis of Its Impact on Bacterial Flora of the Upper Respiratory Tract and Incidence of Infections

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Alina Olender ◽  
Katarzyna Małkińska ◽  
Jacek Roliński ◽  
Ewelina Grywalska ◽  
Elżbieta Pels ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Bacterial Flora ◽  
Carrier State ◽  
Control Group ◽  
Pathogenic Microorganisms ◽  
Upper Respiratory Tract ◽  
Specific Antibodies ◽  
Positive Effects ◽  
Upper Respiratory ◽  
Potentially Pathogenic Microorganisms

S. pneumoniae is a microorganism that may cause a serious threat in postsplenectomy patients due to a potentially invasive course of infection. In order to assess a protective activity after vaccination with the 23-valent vaccine, we made an analysis of the level of antibodies in patients with asplenia compared to a control group of healthy donors. Additionally, colonization by potentially pathogenic microorganisms of the upper respiratory tract was analyzed to determine the carrier state by strains with vaccine serotype. No such strains were found in the research, yet three non-vaccine-serotype strains were found. Colonization of the upper respiratory tract by potentially pathogenic microorganisms may be connected with increased susceptibility observed and incidence of infections in patients with asplenia. However, colonization by S. pneumoniae may not have an effect on the level of specific antibodies with the 23-valent vaccine against S. pneumoniae (PPV23) in postsplenectomy patients and healthy people. The response to vaccination against S. pneumoniae showed a lower level of specific antibodies in patients with splenectomy performed more than 2 years before the test than in patients with a recently removed spleen, i.e., from 1 month to 2 years before the test. Vaccination against pneumococci also has positive effects on incidence of other etiology infections, which is of high significance in the prophylaxis of infectious diseases in this group of patients.

scholarly journals Primary tuberculosis of tonsils: a case report

2015 ◽  
Vol 9 (1) ◽  
pp. 58-59
Author(s):  
Md Rafiqul Islam ◽  
Lipika Sanjowal ◽  
Md Shahriar Islam ◽  
Anika Afrin
Keyword(s):  
Case Report ◽  
Pulmonary Tuberculosis ◽  
Oral Cavity ◽  
Respiratory Tract ◽  
Clinical Entity ◽  
Rare Clinical Entity ◽  
Upper Respiratory Tract ◽  
Primary Tuberculosis ◽  
Active Pulmonary Tuberculosis ◽  
Upper Respiratory

The occurrence of tuberculosis of the upper respiratory tract including oral cavity has become uncommon. Isolated tuberculosis in the absence of active pulmonary tuberculosis is very rare clinical entity. Here is a report of primary tuberculosis of tonsil, presented with complaints of sore throat.Faridpur Med. Coll. J. 2014;9(1): 58-59

scholarly journals Acute viral myositis: case report

2021 ◽  
Author(s):  
Felipe Sarlo Pezzin ◽  
Camila de Melo Perovani ◽  
Luana Marques Ribeiro ◽  
Julya Leite de Assis Pereira ◽  
Caroline Lopes Gratival ◽  
...  
Keyword(s):  
Case Report ◽  
Tract Infection ◽  
Respiratory Tract ◽  
Respiratory Tract Infection ◽  
Nasal Congestion ◽  
Upper Respiratory Tract Infection ◽  
Lower Limbs ◽  
Neurological Deficits ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

Context: Benign Acute Childhood Myositis (BACM) is a self-limited syndrome of acute myalgia prevalent in calf with impaired walking after Upper Respiratory Tract Infection. This report analyze the clinical condition and investigation of BACM case, by medical record. Case report: C.L.F.A., male, 12 years, in use of clobazam, sodium divalproate, topiramate and lamotrigine, started low back pain. One day after, presented headache, fever and nasal congestion. Reported convulsive febrile episodes. At following morning received Upper Respiratory Tract Infection diagnoses. Next day, maintained symptoms and developed thrombocytopenia. Discharged due to suspicion of dengue. After 24 hours, returned with improved thrombocytopenia, also with leukopenia. At 5th day, started pain in lower limbs and impaired walking. Due to muscle symptoms worsening and increased creatinophosphokinase, hospital admission were indicated. Laboratory tests found increased in creatinekinase (10,180 U/L), CKMB (129,6 U/L), leukopenia (2800/mm3 ) and thrombocytopenia (174,000 / mm3 ). Anti-HIV, anti- leptospirosis, dengue, Chikungunya and anti-HCV tests resulted negative. At the 6th hospitalization day, he was discharged virtue of muscle symptoms, leukocytosis and creatinekinase levels favorable progression. Conclusions: BACM has excellent prognosis and self-limited course, so outpatient care is feasible. The diagnosis is clinical. If neurological deficits, modified urine tests and rash, or symptoms duration longer than one week, differential diagnoses must be researched. Measure creatinekinase is important if pain or walking disability after viral episode. Early intervention avoids complications.

scholarly journals Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

2021 ◽  
Author(s):  
Joan E.M. van der Lubbe ◽  
Sietske K. Rosendahl Huber ◽  
Aneesh Vijayan ◽  
Liesbeth Dekking ◽  
Ella van Huizen ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Disease ◽  
Syrian Hamster ◽  
Vaccine Dose ◽  
Neutralizing Antibody ◽  
Upper Respiratory Tract ◽  
Breakthrough Infection ◽  
Syrian Hamsters ◽  
Antibody Titers ◽  
Upper Respiratory

Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1x109 vp and 1x1010 vp elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers which was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these pre-clinical data confirm efficacy of a 1-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.

Sign in / Sign up

Export Citation Format

Share Document